Senores Pharmaceuticals Limited

Mahindra Manulife Mutual Fund decreased its stake in Senores Pharmaceuticals Limited from 1.40% to 1.14%, selling 123,337 shares for ₹17.34 Cr at ₹1405.10 apiece.

A pharmaceutical manufacturer that produces complex generic medicines certified by global regulatory authorities including the FDA and WHO. Incorporated in 2015, the company focuses on developing and supplying affordable, high-quality pharmaceutical formulations to domestic and international markets. Its operations center on manufacturing specialized generics that address critical therapeutic areas while maintaining stringent international quality standards and compliance requirements.

Joint venture between Mahindra Group and Manulife Investment Management of Canada. Manages over Rs 30,000 crore. Focuses on equity and hybrid fund strategies with a quality growth bias inherited from the Manulife global investment framework. Leverages the Mahindra Group's brand and distribution reach for retail investor outreach.